The A-rich RNA sequences of HIV-1 pol are important for the synthesis of viral cDNA

Nucleic Acids Research

Volumn 37, Issue 3, 2009, Pages 945-956

  Keating, Cameron P ^a   Hill, Melissa K ^a,b   Hawkes, David J ^a,b   Smyth, Redmond P ^a,b   Isel, Catherine ^c   Le, Shu Yun ^d   Palmenberg, Ann C ^e   Marshall, John A ^f   Marquet, Roland ^c   Nabel, Gary J ^g   Mak, Johnson ^a,b  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; POL PROTEIN; VIRUS DNA; VIRUS PROTEIN; ADENINE; VIRUS RNA;

ARTICLE; CODON; CONTROLLED STUDY; DNA SYNTHESIS; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; RNA SEQUENCE; RNA STRUCTURE; VIRION; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS MUTATION; BIOSYNTHESIS; CELL LINE; CHEMISTRY; CONFORMATION; DIMERIZATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; REGULATORY RNA SEQUENCE; STRUCTURAL GENE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENINE; BASE SEQUENCE; CELL LINE; CODON; DIMERIZATION; DNA, COMPLEMENTARY; DNA, VIRAL; GENES, POL; HIV-1; HUMANS; NUCLEIC ACID CONFORMATION; REGULATORY SEQUENCES, RIBONUCLEIC ACID; REVERSE TRANSCRIPTION; RNA, VIRAL; VIRAL PROTEINS; VIRION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 63349106458     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkn1015     Document Type: Article

References (72)

1. Mattick,J.S. (2005) The functional genomics of noncoding RNA. Science 309, 1527-1528.
2. Matera,A.G., Terns,R.M. and Terns,M.P. (2007) Non-coding RNAs: Lessons from the small nuclear and small nucleolar RNAs. Nat. Rev. Mol. Cell Biol., 8, 209-220.
3. Amaral,P.P., Dinger,M.E., Mercer,T.R. and Mattick,J.S. (2008) The eukaryotic genome as an RNA machine. Science, 319, 1787-1789.
4. Mattick,J.S. and Makunin,I.V. (2006) Non-coding RNA. Hum. Mol. Genet. 15(Spec No. 1), R17-R29.
5. Gottwein,E. and Cullen,B.R. (2008) Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 3, 375-387.
6. Haasnoot,J., Westerhout,E.M. and Berkhout,B. (2007) RNA interference against viruses: Strike and counterstrike. Nat. Biotechnol., 25 1435-1443.
7. Jenkins,G.M. and Holmes,E.C. (2003) The extent of codon usage bias in human RNA viruses and its evolutionary origin. Virus Res., 92 1-7.
8. Berkhout,B. and Van Hemert,F.J. (1994) The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. Nucleic Acids Res., 22, 1705-1711.
9. Berkhout,B., Grigoriev,A., Bakker,M. and Lukashov,V.V. (2002) Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure. AIDS Res. Hum. Retroviruses, 18, 133-141.
10. van Hemert,F.J. and Berkhout,B. (1995) The tendency of lentiviral open reading frames to become A-rich: Constraints imposed by viral genome organization and cellular tRNA availability. J. Mol. Evol., 41 132-140.
11. Vartanian,J.P., Henry,M. and Wain-Hobson,S. (2002) Sustained G - a hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J. Gen. Virol., 83, 801-805.
12. Grantham,P. and Perrin,P. (1986) AIDS virus and HTLV-I differ in codon choices. Nature, 319, 727-728.
13. Sharp,P.M. (1986) What can AIDS virus codon usage tell us? Nature, 324, 114.
14. Kypr,J. and Mrázek,J. (1987) Unusual codon usage of HIV. Nature 327, 20.
15. Martinez,M.A., Vartanian,J.P. and Wain-Hobson,S. (1994) Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl Acad. Sci. USA, 91 11787-11791.
16. Vartanian,J.P., Plikat,U., Henry,M., Mahieux,R., Guillemot,L., Meyerhans,A. and Wain-Hobson,S. (1997) HIV genetic variation is directed and restricted by DNA precursor availability. J. Mol. Biol., 270, 139-151.
17. Mansky,L.M. and Temin,H.M. (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol., 69, 5087-5094.
18. Harris,R.S., Bishop,K.N., Sheehy,A.M., Craig,H.M., Petersen-Mahrt, S.K., Watt,I.N., Neuberger,M.S. and Malim,M.H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell, 113, 803-809.
19. Sheehy,A.M., Gaddis,N.C. and Malim,M.H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med., 9, 1404-1407.
20. Zhang,H., Yang,B., Pomerantz,R.J., Zhang,C., Arunachalam,S.C. and Gao,L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature, 424, 94-98.
21. Yu,Q., Konig,R., Pillai,S., Chiles,K., Kearney,M., Palmer,S., Richman,D., Coffin,J.M. and Landau,N.R. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol., 11, 435-442.
22. Lee,Y.N., Malim,M.H. and Bieniasz,P.D. (2008) Hypermutation of an ancient human retrovirus by APOBEC3G. J. Virol., 82, 8762-8770.
23. Jones,K.L. and Mak,J. (2005) Innate immunity and intracellular trafficking: Insights for novel anti-HIV-1 therapeutics. Curr. Pharmacogenomics, 3, 97-117.
24. Yu,Q., Chen,D., Konig,R., Mariani,R., Unutmaz,D. and Landau,N.R. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem., 279, 53379-53386.
25. Sheehy,A.M., Gaddis,N.C., Choi,J.D. and Malim,M.H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 418, 646-650.
26. Adachi,A., Gendelman,H.E., Koenig,S., Folks,T., Willey,R., Rabson,A. and Martin,M.A. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol., 59, 284-291.
27. Huang,Y., Kon,W.-P. and Nabel,G.J. (2001) Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol., 75, 4947-4951.
28. Shehu-Xhilaga,M., Crowe,S.M. and Mak,J. (2001) Maintenance of the Gag/ Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J. Virol., 75, 1834-1841.
29. Goff,S., Traktman,P. and Baltimore,D. (1981) Isolation and properties of Moloney murine leukemia virus mutants: Use of a rapid assay for release of virion reverse transcriptase. J. Virol., 1, 239-248.
30. Hill,M.K., Shehu-Xhilaga,M., Campbell,S.M., Poumbourios,P., Crowe,S.M. and Mak,J. (2003) The dimer initiation sequence stem-loop of human immunodeficiency virus type 1 is dispensable for viral replication in peripheral blood mononuclear cells. J. Virol., 77, 8329-8335.
31. Shehu-Xhilaga,M., Kraeusslich,H.G., Pettit,S., Swanstrom,R., Lee,J.Y., Marshall,J.A., Crowe,S.M. and Mak,J. (2001) Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type1 RNA dimer maturation. J. Virol., 75, 9156-9164.
32. Shehu-Xhilaga,M., Hill,M., Marshall,J.A., Kappes,J., Crowe,S.M. and Mak,J. (2002) The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein. J. Virol., 76, 4331-4340.
33. Hill,M.K., Shehu-Xhilaga,M., Crowe,S.M. and Mak,J. (2002) Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability. J. Virol., 76, 11245-11253.
34. Fu,W. and Rein,A. (1993) Maturation of dimeric viral RNA of Moloney murine leukemia virus. J. Virol., 67, 5443-5449.
35. Fu,W., Gorelick,R.J. and Rein,A. (1994) Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. J. Virol., 68, 5013-5018.
36. Buxton,P., Tachedjian,G. and Mak,J. (2005) Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation. J. Virol., 79, 6338-6348.
37. Zack,J.A., Arrigo,S.J., Weitsman,S.R., Go,A.S., Haislip,A. and Chen,I.S. (1990) HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell, 61, 213-222.
38. Victoria,J.G., Lee,D.J., McDougall,B.R. and Robinson,W.E. Jr. (2003) Replication kinetics for divergent type 1 human immunodeficiency viruses using quantitative SYBR green I real-time polymerase chain reaction. AIDS Res. Hum. Retroviruses, 19, 865-874.
39. Zhang,L., Lewin,S.R., Markowitz,M., Lin,H.H., Skulsky,E., Karanicolas,R., He,Y., Jin,X., Tuttleton,S., Vesanen,M. et al. (1999) Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J. Exp. Med., 190, 725-732.
40. Marquet,R., Baudin,F., Gabus,C., Darlix,J.-L., Mougel,M., Ehresmann,C. and Ehresmann,B. (1991) Dimerization of human immunodeficiency virus (Type 1) RNA: Stimulation by cations and possible mechanism. Nucleic Acids Res., 19, 2349-2357.
41. Felber,B.K., Zolotukhin,A.S. and Pavlakis,G.N. (2007) Posttranscriptional control of HIV-1 and other retroviruses and its practical applications. Adv. Pharmacol., 55, 161-197.
42. Mouland,A.J., Xu,H., Cui,H., Krueger,W., Munro,T.P., Prasol,M., Mercier,J., Rekosh,D., Smith,R., Barbarese,E. et al. (2001) RNA trafficking signals in human immunodeficiency virus type 1. Mol. Cell Biol., 21, 2133-2143.
43. Beriault,V., Clement,J.F., Levesque,K., Lebel,C., Yong,X., Chabot,B., Cohen,E.A., Cochrane,A.W., Rigby,W.F. and Mouland,A.J. (2004) A late role for the association of hnRNP A2 with the HIV-1 hnRNP A2 response elements in genomic RNA, Gag, and Vpr localization. J. Biol. Chem. 279, 44141-44153.
44. Levesque,K., Halvorsen,M., Abrahamyan,L., Chatel-Chaix,L., Poupon,V., Gordon,H., DesGroseillers,L., Gatignol,A. and Mouland,A.J. (2006) Trafficking of HIV-1 RNA is mediated by heterogeneous nuclear ribonucleoprotein A2 expression and impacts on viral assembly. Traffic, 7, 1177-1193.
45. Jacks,T., Power,M.D., Masiarz,F.R., Luciw,P.A., Barr,P.J. and Varmus,H.E. (1988) Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature, 331, 280-283.
46. Zennou,V., Petit,C., Guetard,D., Nerhbass,U., Montagnier,L. and Charneau,P. (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell, 101, 173-185.
47. Arhel,N.J., Souquere-Besse,S., Munier,S., Souque,P., Guadagnini,S., Rutherford,S., Prevost,M.C., Allen,T.D. and Charneau,P. (2007) HIV-1 DNA flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J., 26, 3025-3037.
48. Wang,Q., Barr,I., Guo,F. and Lee,C. (2008) Evidence of a novel RNA secondary structure in the coding region of HIV-1 pol gene. RNA, 14, 2478-2488.
49. Le,S.Y., Chen,J.H., Konings,D. and Maizel,J.V. Jr. (2003) Discovering well-ordered folding patterns in nucleotide sequences. Bioinformatics 19, 354-361.
50. Kotsopoulou,E., Kim,V.N., Kingsman,A.J., Kingsman,S.M. and Mitrophanous,K.A. (2000) A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol., 74, 4839-4852.
51. Wagner,R., Graf,M., Bieler,K., Wolf,H., Grunwald,T., Foley,P. and Uberla,K. (2000) Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: Implications for the safety of lentiviral vectors. Hum. Gene Ther., 11, 2403-2413.
52. Cavrois,M., De Noronha,C. and Greene,W.C. (2002) A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol., 20, 1151-1154.
53. Paillart,J.C., Shehu-Xhilaga,M., Marquet,R. and Mak,J. (2004) Dimerization of retroviral RNA genomes: An inseparable pair. Nat. Rev. Microbiol., 2, 461-472.
54. Berkhout,B. (2000) Multiple biological roles associated with the repeat (R) region of the HIV-1 RNA genome. Adv. Pharmacol., 48, 29-73.
55. Yeung,M.L., Bennasser,Y., Le,S.Y. and Jeang,K.T. (2007) RNA interference and HIV-1. Adv. Pharmacol., 55, 427-438.
56. Abbink,T.E. and Berkhout,B. (2007) HIV-1 reverse transcription: Close encounters between the viral genome and a cellular tRNA. Adv. Pharmacol., 55, 99-135.
57. Lever,A.M. (2007) HIV-1 RNA packaging. Adv. Pharmacol., 55, 1-32.
58. Schneider,R., Campbell,M., Nasioulas,G., Felber,B.K. and Pavlakis,G.N. (1997) Inactivation of the human immunodeficiency virus type 1 inhibitory elements allow Rev-independent expression of Gag and Gag/ protease and particle formation. J. Virol., 71, 4892-4903.
59. Schwartz,S., Felber,B.K. and Pavlakis,G.N. (1992) Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs. Mol. Cell Biol., 12, 207-219.
60. Christensen,H.S., Daher,A., Soye,K.J., Frankel,L.B., Alexander,M.R., Laine,S., Bannwarth,S., Ong,C.L., Chung,S.W., Campbell,S.M. et al. (2007) Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production. J. Virol., 81 5121-5131.
61. Haasnoot,J., de Vries,W., Geutjes,E.J., Prins,M., de Haan,P. and Berkhout,B. (2007) The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog., 3, e86.
62. Triboulet,R., Mari,B., Lin,Y.L., Chable-Bessia,C., Bennasser,Y., Lebrigand,K., Cardinaud,B., Maurin,T., Barbry,P., Baillat,V. et al. (2007) Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science, 315, 1579-1582.
63. Berkhout,B. and Jeang,K.T. (2007) RISCy business: MicroRNAs, pathogenesis, and viruses. J. Biol. Chem., 282, 26641-26645.
64. Graf,M., Bojak,A., Deml,L., Bieler,K., Wolf,H. and Wagner,R. (2000) Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol., 74, 10822-10826.
65. Sheng,N. and Erickson-Viitanen,S. (1994) Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent. J. Virol., 68, 6207-6214.
66. Sheng,N., Pettit,S.C., Tritch,R.J., Ozturk,D.H., Rayner,M.M., Swanstrom,R. and Erickson-Viitanen,S. (1997) Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J. Virol., 71, 5723-5732.
67. Lear,A.L., Haddrick,M. and Heaphy,S. (1995) A study of the dimerization of Rous sarcoma virus RNA in vitro and in vivo. Virology, 212 47-57.
68. Ortiz-Conde,B.A. and Hughes,S.H. (1999) Studies of the genomic RNA of leukosis viruses: Implications for RNA dimerization. J. Virol., 73, 7165-7174.
69. Sakuragi,J.-I. and Panganiban,A.T. (1997) Human immunodeficiency virus type 1 RNA outside the primary encapsidation and dimer linkage region affects RNA dimer stability in vitro. J. Virol., 71, 3250-3254.
70. Roy,B.B., Hu,J., Guo,X., Russell,R.S., Guo,F., Kleiman,L. and Liang,C. (2006) Association of RNA helicase a with human immunodeficiency virus type 1 particles. J. Biol. Chem., 281, 12625-12635.
71. Paillart,J.C., Berthoux,L., Ottmann,M., Darlix,J.L., Marquet,R., Ehresmann,B. and Ehresmann,C. (1996) A dual role of the putative RNA dimerization initation site of human immunodeficiency virus type 1 in genomic RNA packaging and proviral DNA synthesis. J. Virol., 70 8348-8354.
72. Palmenberg,A.C. and Sgro,J.Y. (1998) Topological organization of picornaviral genomes: Statistical prediction of RNA structural signals. Semin. Virol., 8, 231-241.